Company
Melbourne, VIC
Every investor coverage indicates participated in a round WEHI raised.
Companies WEHI acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| David Komander | Head of the Ubiquitin Signalling Division | Brandon Capital portfolio |
| Dr Anne-Laure Puaux | Head of Biotechnology and Commercialisation | Brandon Capital portfolio |
| Dr Sara Prickett | Postdoctoral Researcher (former) | Brandon BioCatalyst |
| Ueli Nachbur | Scientist Entrepreneur | Brandon Capital portfolio |
Stories naming WEHI. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Breakthrough Victoria's chief executive marks his first year, tallying 70 investments, university and fellowship programs, a Jumar Bioincubator grant with partners, and looks ahead to a consolidated Victorian innovation entity.
Profile tracing Sara Prickett's path from UK labs to co-founding Aravax, the peanut-allergy biotech Brandon Capital backed, as its Phase II trial nears readout in mid-2026.
A profile of Brandon Capital partner Chris Smith, tracing his path from immunology research and a Cambridge postdoc into biotech investing, with resilience lessons drawn from equestrian sport and companies Aravax and ENA Respiratory.
Profile of Australian biotech startup Proxima Bio, covering its founding, an early MRFF grant through the CUREator program, Brandon Capital's guidance, and a later larger investment that grew the team.
A profile of six life-science ventures that graduated from Melbourne bioincubator Jumar's debut program, one of which, Tessara Therapeutics, won a $3 million research grant in December.
Profile of scientist-entrepreneur Andrew Wilks covering the GSK sale of his cancer molecule, his SYNthesis BioVentures fund's family-office backers, and portfolio plays including Aculeus Therapeutics.
Cicada Innovations is opening a health-tech incubator at Sydney's Westmead precinct with NSW government grant backing, working with Brandon Capital and Brandon BioCatalyst to help researchers commercialise medical discoveries.
Deep tech incubator Cicada Innovations is opening a health-focused facility at Sydney's Westmead precinct with Investment NSW backing, working with Brandon Capital and Brandon BioCatalyst to help early medical startups commercialise.
Debut quarterly letter from SYNthesis BioVentures reporting A$18 million committed to its fund, an A$3.8 million stake in Catalyst Therapeutics' A$11.7 million seed round, and two senior appointments from the SYNthesis Group.
Profile of Cairns startup Rainstick, which uses artificial lightning to boost mushroom growth. It won $20,000 from Dream Ventures, has taken in $200,000, and joined CSIRO's ON Accelerate with nine other teams.
CSIRO has revived its ON Accelerate program and named ten deep-tech startup teams, drawn from universities and its own research, joining the seventh cohort starting in early 2023.
Biotech startup Entact Bio has launched with an $81 million Series A funding its Encompass platform, which designs molecules that enhance protein function, backed by Qiming Venture Partners USA, venBio Partners and others.
The MRCF, managed by publisher Brandon Capital, has launched a government-funded national biotech incubator with committed funding, and appointed a new Head of Operations, with applications now open for its first intake.
Calix received a $1 million federal grant for its Bacchus Marsh biotech operations, while CSL is dedicating floors of its new Melbourne headquarters to a biotechnology incubator with university and research institute partners.
A 2007 announcement that Australian biotech ChemGenex Pharmaceuticals appointed former Amgen executive Dr George Morstyn to its board, with CEO Greg Collier citing his oncology development and commercialisation expertise.